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Background: Randomized controlled trials (RCTs) often recruit patients from low and high socioeconomic status 
(SES) countries, but little is known about the effect of SES on clinical outcomes, particularly patient-centered 
measures of symptomatic benefit.
Methods: Combined individual chronic obstructive pulmonary disease (COPD) patient data from the placebo and 
long-acting bronchodilator arms of 17 RCTs (from the COPD Biomarkers Qualification Consortium database) 
were analyzed. Health status was measured using the St George’s Respiratory Questionnaire (SGRQ) (minimum 
clinically important difference [MCID]: 4 units). Trials were grouped into short-term (≤12 months) and medium-
term (>12 months to 48 months). A participant’s country of residence was categorized into Low/Medium or High 
SES using World Health Organization criteria. 
Results: Data from 19765 individuals (6109 Low/Medium SES) were available. Patients in Low/Medium SES 
countries had more severe disease at baseline. Improvement in SGRQ score with placebo was ≈2 units greater in 
Low/Medium than in High SES countries; at its greatest, the improvement from baseline exceeded the MCID in 
Low/Medium countries. This difference was maintained for at least 1 year. Improvement with bronchodilator was 
also greater in Low/Medium versus High SES countries; overall there was no evidence that the treatment effect 
versus placebo was different between countries of different SES status.
Conclusions: Participants in Low/Medium SES countries experienced significantly larger treatment effects, 
irrespective of treatment group (placebo and bronchodilator). Despite this, COPD patients in Low/Medium SES 
countries experienced a health status gain from long-acting bronchodilator treatment that is similar to that seen 
in High SES countries.
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Introduction
Many clinical trials in chronic obstructive pulmonary 
disease (COPD) are conducted globally, recruiting 
patients from multiple countries and representing 
varied populations, including those with both lower and 
higher socioeconomic status (SES).1,2 Patients with 
lower SES have poorer outcomes that is multi-factorial 
in origin, but is likely to include less access to health 
care.3 In countries with lower SES, patients entering 
a clinical trial may move into a system of health care 
similar to that found in highly developed countries. 
Increasing numbers of trials are now being performed 
solely in countries with developing economies, in 
which recruited patients may be naïve to the class of 
drug being tested.4 These factors could all impact the 
measured response to treatment.
Health status instruments such as the St George’s 
Respiratory Questionnaire (SGRQ)5 are often used to 
quantify the overall benefit of treatment by providing 
a standardized measure of the impact of disease on 
patients’ wellbeing and daily activities.6,7 It can be used 
across patient groups and was designed to provide a 
score that is not influenced by the mode of therapeutic 
action, thereby permitting comparisons of treatment 
effect across populations and modalities.7 When 
used together with its minimum clinically important 
difference (MCID), its scores can provide an indication 
of whether the treatment effect is worthwhile.8,9 In 
Methods
Identification of Clinical Trials
Studies where SGRQ was included as an outcome 
were identified in the COPD Biomarkers Qualification 
Consortium (CBQC) database of clinical trials in 
COPD.14 Twenty-one studies were identified with 
SGRQ scores measured at baseline and during follow-
up in each trial arm: 18 randomized controlled trials 
(RCTs) and 3 observational studies. For the current 
analysis, RCTs that included an intervention arm with 
long-acting bronchodilators only (long-acting beta2-
agonists and long-acting anti-muscarinic agents) or 
placebo were evaluated (N=17). The observational 
studies were not incorporated in this analysis, nor were 
other treatment arms. Details of the RCTs included in 
the analysis are described elsewhere.15 All participants 
in these trials who had a baseline SGRQ score were 
included in these analyses.
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clinical trials, changes are often seen in the placebo 
arm across a range of outcomes, particularly those 
that measure symptoms and health status10,11 The 
responsible mechanisms are not well understood, 
but are likely to include better care and a Hawthorne 
effect,12 in which the patient’s (and perhaps their health 
care provider’s) behavior changes due to the fact that 
they are being observed. Such changes could include: 
better compliance with, and use of, trial-permitted 
concomitant therapy, earlier treatment of acute episodes, 
and adoption of a healthier life style including smoking 
cessation. 
The effects due to trial participation, coupled with the 
possible influences of SES on health outcomes, raise 
important questions for the interpretation of clinical trial 
results from countries of differing SES. For example: Do 
patients recruited from low SES countries experience 
the same benefit as those in wealthier countries? Does 
the clinical trial effect differ between countries of high 
and low SES? Is the size of the measured treatment effect 
influenced by SES? Can therapeutic data from countries 
of differing SES be combined to produce a meaningful 
dataset? 
To address these questions in COPD - a common, 
chronic and worldwide condition13 - we carried out a 
pooled analysis using individual patient clinical trial 
data from a newly created comprehensive database 
using the SGRQ as the outcome measure.5 The SGRQ 
is particularly suitable for this type of analysis since it 
is very widely used and available in many linguistically 
and culturally validated translations.
5 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, 
Connecticut 
6 Division of Pulmonary, Critical Care, Sleep and Allergy, Nebraska 
Medical Center, Omaha
7 Research and Development, GlaxoSmithKline, King of Prussia, 
Pennsylvania
8 COPD Foundation, Washington, D.C.
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The 17 RCTs were grouped by study duration, 
categorized as short-term (≤1-year duration) comprising 
14 trials with 10802 COPD patients (placebo=3670; 
bronchodilator=7132), and medium-term (2-4 years 
in duration) comprising 3 trials with 8963 patients 
(placebo=4184; bronchodilator=4779). Comparable 
numbers of study participants are included in each 
category. The 2 groups of trials were analyzed separately 
to test for consistency of findings across studies of 
different duration. The World Health Organization 
(WHO) socioeconomic grading system was used to 
group countries into High and Low/Medium SES (the 
latter 2 combined to achieve a similar balance of patient 
numbers between groups).16
Outcome Measures
The main outcome of interest was SGRQ total score. 
A range of other demographic and disease-related 
measures were available, including forced expiratory 
volume in 1 second (FEV1), modified Medical Research 
Council (mMRC) dyspnea score and history of COPD 
exacerbations. 
Statistical Analysis
For each of the short-term and medium-term analysis 
samples used in the current analysis, demographic 
characteristics are presented as mean and standard 
deviation (SD). Analysis of covariance (ANCOVA) 
models were conducted with treatment, SES status, and 
treatment x SES status as independent variables, and 
change from baseline in SGRQ score as the dependent 
variable to evaluate the impact of SES status on SGRQ. 
Sex, body mass index (BMI), year of study, smoking 
status (current versus past), Global initiative for chronic 
Obstructive Lung Disease (GOLD) FEV1 grade,13 and 
baseline SGRQ score were included as covariates. 
Separate models were conducted for different time 
points. In the short-term dataset, models were conducted 
with change from baseline to 1, 3, 6 and 12 months. 
In the medium-term dataset, models were conducted 
with change from baseline to 6, 12, 24, and 36 months. 
Scheffe tests were used for post-hoc comparisons.
Results
Baseline Characteristics 
The baseline demographics of the patients were similar 
between SES groups, although in Low/Medium SES 
countries the proportion of males was higher and the 
patients were slightly younger (by approximately 2 
years) (Tables 1 and 2). In the short-term trials, patients 
in Low/Medium SES countries had more severe disease 
as shown by FEV1, SGRQ score, mMRC dyspnea score, 
COPD exacerbation rate and hospitalizations due 
to exacerbation; although generally the differences 
were not clinically important (Table 1). The 2.0 unit 
difference in mean SGRQ total score between groups 
at baseline shows that, on average, the health status of 
patients from Low/Medium SES countries was worse 
than in those from High SES countries at entry to the 
study, but the difference did not reach the MCID. 
A similar pattern was observed in the medium-term 
trials, with the exception that the mean difference in 
SGRQ was 3.5, showing that at study entry, patients 
from Low/Medium SES countries had health status 
that was clearly worse than that of participants from 
High SES countries (Table 2). There was no difference 
in FEV1 between the SES groups in the medium-term 
trials, but patients from Low/Medium SES countries 
reported worse dyspnea grades, more exacerbations 
and more hospitalizations due to an exacerbation.
Patient Withdrawal Rates
The withdrawal rate in Low/Medium SES countries was 
almost half that seen in High SES countries. In short-
term trials the dropout rates (placebo and bronchodilator 
combined) were: Low/Medium SES 20% (496/2476); 
High SES 37% (1828/4927). In the medium-term trials 
the dropout rates were similar to those seen in the short-
term trials: Low/Medium SES 18% (363/2040); High 
SES 34% (2312/6823).
Response to Placebo
A significant improvement in mean SGRQ score was 
seen with placebo in Low/Medium and High SES 
countries in both short-term and medium-term trials 
(Figures 1A & 2A). The pattern was different between 
short- and medium-term trials. In the short-term trials 
(Figure 1A), the improvement developed progressively 
to be maximal at 3-6 months; it exceeded the 4-unit 
MCID in countries with Low/Medium SES. The greater 
response in Low/Medium SES countries was statistically 
significant, even at 1 month and at 3-6 months it was over 
2 units more than that seen in the High SES countries. 
The wide and overlapping 95% confidence intervals at 
12 months was associated with a much smaller number 
of patients which precludes any firm inferences being 
drawn at this time point. 
In the medium-term trials (Figure 2A), the 
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improvement was similar in both groups of patients 
and around 2 units. This effect was maintained for 12 
months, but was gone by 36 months in both groups. It 
is noteworthy that a similar pattern can been seen at 6 
and 12 months in both groups of studies. During that 
interval, there is a trend for the patients in the High 
SES group to worsen, but for the improvement to be 
maintained up to 12 months in the Low-Medium SES 
group
Treatment Response to Long-acting 
Bronchodilator
There was a significant main effect for treatment in 
each of the ANCOVA models for the short-term and 
medium-term studies (all p values <0.001), with greater 
improvement in SGRQ over time in bronchodilator 
relative to placebo. In the short-term trials (Figure 1B), 
there was a significant improvement from baseline, 
which either attained (High SES) or well-exceeded (Low/
Medium SES) the 4-unit MCID, and in both groups of 
patients this benefit was maintained for 12 months. 
The difference in response to bronchodilator between 
groups increased up to 6 months and was statistically 
significant at all time points. At 6 and 12 months, the 
difference was over 3 units. There was a similar pattern 
of sustained difference over 3 years (Figure 2B), but it 
was smaller (≈1.5 units) and only statistically significant 
at 6 and 12 months (Table 3).
Treatment x Socioeconomic Response
The interaction between treatment versus placebo and 
SES group was not significant in the majority of the 
analyses, with 1 exception. In the medium-term dataset 
when evaluating change from baseline to 36 months 
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the difference between bronchodilator and placebo was 
significantly greater in the Low/Medium SES patients 
(Table 3). This may be related to the fact that patients 
in the Low SES group receiving placebo initially 
experienced a greater improvement relative to those in 
the High SES group, but by month 36 they experienced 
a greater deterioration relative to patients in High SES 
groups (Figures 2A & B).
Discussion
This is the first major analysis of the effect of 
socioeconomic status on health status in response to 
treatment for COPD. It shows that individuals from both 
High and Low/Medium SES countries experience an 
improvement in health status on entering a clinical trial, 
even if they receive placebo. This effect is larger and 
appears to be sustained for longer in study participants 
from Low/Medium SES countries, although it is lost 
after 2 years. With long-acting bronchodilator treatment 
there is an improvement from baseline that almost 
reaches (High SES) or exceeds (Low-Medium SES) the 
4 unit SGRQ MCID, thereafter the improvement in the 
High SES patients is relatively small (< 1 unit), but in 
Low-Medium SES patients it appears to be larger (>2 
units).  
The greater improvement in Low-Medium SES 
patients is maintained for 3 years; however, there 
appears to be no difference in treatment response 
compared to placebo, since the larger clinical trial 
effect with placebo is matched by a larger active 
treatment effect. The only possible exception to this 
is at 36 months and is due to the greater worsening 
in placebo treated patients in the Low-Medium SES 
group. It is known that SGRQ deteriorates over time 
and the apparently greater worsening in Low-Medium 
SES patients may be a function of the lower withdrawal 
rate in this group, since it is known that patients with 
worse SGRQ scores are more likely to withdraw early 
from a trial.17 Overall, these results suggest that data 
from patients in countries of different SES status may 
be combined and that results from one country should 
be generalizable to countries of different SES status. 
At baseline, study participants in Low/Medium 
SES countries had slightly more severe COPD across 
a range of measures, including SGRQ score, but the 
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differences were small and largely consistent between 
short- and medium-term studies. Previously, we have 
shown that demographic factors other than SES have a 
very small effect on SGRQ scores.18 The mean baseline 
SGRQ scores in the patients analyzed here were in the 
range 46-48 units, which is in contrast to a mean score 
of 64.8 reported in an audit of severe COPD patients in 
a routine care setting in the United States.19 Whereas 
in an observational study in China, the baseline SGRQ 
score was 46.3 units20 suggesting that in both higher 
and lower SES countries, the more severe patients are 
not recruited to clinical studies. 
The onset of the clinical trial effect appeared to 
follow a relatively consistent pattern across countries, 
increasing to a maximum at around 6 to 12 months. It 
was progressive in onset, rather than being apparent 
from the outset of the trial, which suggests that the 
benefit was acquired progressively over time, rather than 
as a step response to entering the study. The effect was 
larger and sustained for longer in poorer countries. The 
responsible mechanisms cannot be identified from this 
analysis, but a Hawthorne effect12 producing changes in 
health behaviors and treatment compliance on entering 
a trial is one possible factor. In addition, a patient may 
have an improved sense of confidence in their ability 
to manage their disease, since on joining the trial they 
gain access to free and regular health care, which they 
may not have experienced previously. In support of this 
conclusion is the demonstration that more intensive 
monitoring during a randomized trial was associated 
with a better outcome compared to that seen in patients 
who received the same pharmacological treatment, but 
less intensive monitoring.21
This analysis used individual participant data, rather 
than a meta-analysis of reported study results, but it 
does have limitations. All the trials were randomized 
and double blind, so the treatment arms will have been 
well-matched at an individual trial level, but differing 
trial durations and different dropout rates would have 
led to the treatment groups becoming less well matched 
over time. However, it is noteworthy that the overall 
pattern of results was very similar in trials of quite 
different duration. The assessment time-points differed 
between trials, so not all patients were assessed at each 
time point, however; the large sample sizes appear 
to have minimized this effect at a group level, since 
the time trends showed quite smooth curves across 
the assessment points. Another limitation is our use 
of the World Health Organization classification for 
determining a country’s health care system, since the 
proportion of gross domestic product spent on health 
varies a great deal between countries. More importantly, 
it treats each patient as having the same SES status. 
Within all countries there is a wide variation in income 
and the effect of this on health may be increasing since 
a widening mortality gap was shown in Canada between 
1996/7 and 2012/3 in COPD patients with low SES 
compared to those who were more affluent.22 Despite 
this limitation, we have shown, in 2 separate analyses 
in a large number of individuals, that the pattern in the 
results appeared remarkably consistent.
These findings have implications for those involved in 
performing and evaluating clinical trials. Any influence 
of SES on the size of treatment effect compared with 
placebo appears to be relatively small. The inclusion of 
patients from Low/Medium SES countries into multi-
national trials with patients from High SES countries 
should not greatly influence the size of effect compared 
to a study that recruited patients solely from High SES 
countries. This conclusion is supported by an analysis 
of one of the primary trials included here, which showed 
that world region did not influence the size of treatment 
effect on SGRQ.23 The current analysis also shows that 
there may be an advantage to the recruitment of patients 
from Low/Medium SES countries, since they have lower 
withdrawal rates, which would reduce the effect of an 
important uncontrolled bias in the trials. 
Finally, this analysis shows that in a chronic disease, 
such as COPD, a patient’s health may be improved by a 
substantial amount just through regular clinical review 
without additional treatment, whether in a higher or 
lower income country. There is a broader message here 
for all health care systems
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